Month: September 2021

  In accordance with the rules on financial transparency*, Fosun has notified Ageas on 29 September 2021 that, on 23 September 2021, its interest has exceeded the legal threshold of 10% of the shares issued by Ageas. Its current total shareholding stands at 10.01%. * article 14, paragraph 1 of the law of 2 May 2007 on disclosure of major holdings us provisions. This press release and the notifications received by Ageas are available on the website.   Ageas is a listed international insurance Group with a heritage spanning almost 200 years. It offers Retail and Business customers Life and Non-Life insurance products designed to suit their specific needs, today and tomorrow. As one of Europe’s larger insurance companies, Ageas concentrates its activities in Europe and Asia, which together make up the major part of the global insurance...

Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and commercialisation company, today announces its unaudited interim results for the six months ended 30 June 2021. Richard Marsden, CEO of Synairgen, said: “The need for an effective, broad-spectrum antiviral to treat patients hospitalised due to COVID-19 remains urgent. While vaccines have played an important role in reducing many of the risks associated with the SARS-CoV-2 virus, thousands of patients continue to require hospital treatment in the US and Europe every day with acute symptoms from COVID-19. This, coupled with the potential of waning immunity...

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, September 30, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba®) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis. The filing triggers a CHF 5 million milestone payment from Asahi Kasei Pharma to Basilea. David Veitch, Chief Executive Officer, said: “We congratulate our partner Asahi Kasei Pharma on the filing of the NDA for isavuconazole in Japan. This is a significant step towards the goal to make isavuconazole available for patients in Japan, which is one of the commercially most important market opportunities for the brand.” The partnership between...

Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in health outcomesContinued our global health leadership with positive phase 2b results for our next generation antimalarial therapy ganaplacide in combination with lumefantrine which support its continued developmentCommitted to achieving net zero carbon emissions across our value chain by 2040Basel, September 30, 2021 — At its eighth annual ESG investor event hosted today, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical...

PGS has 3D seismic data, acquired in partnership with Agência Nacional de Petróleo, Gás e Biocombustíveis (ANPG), covering most of the available opportunities in the Angola 2021 bid round for offshore Kwanza and Lower Congo Basin, announced this month. The round, under Angola’s Petroleum Activities Law, seeks to award eight areas. The PGS data library coverage uses a combination of 3D GeoStreamer technology and modern imaging techniques to unlock plays and opportunities in the blocks on offer.Blocks 7/21 and 8/21 on Kwanza Shelf revealed in 3D GeoStreamer quality Block 16/21 in the Lower Congo Basin revealed in 3D GeoStreamer coverage Block 34/21 Lower Congo Basin covered by conventional 3D data MegaSurvey | Regional coverage of 45 000 sq. km with information on thickness trends, structural setting, depositional environments, and play...

Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline Clinical data complement previous findings in hospitalised setting, including from United Kingdom (UK) University of Oxford-led RECOVERY trialBasel, 30 September 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospitalised with COVID-19. The trial met its primary endpoint, showing that Ronapreve significantly reduced viral load within seven days of treatment in patients who had not mounted a natural antibody response of their own (seronegative) and who required low-flow or no supplemental oxygen (p=0.0172)....

During the virtual Arcadis Sustainability Day event, held today between 16:00 – 17:30 pm CET (registration link), we will discuss:Our commitment to accelerate the transition to a net zero world Our ability to address client needs resulting from climate change Our approach to working with our clients to support their sustainability strategies and implement practical solutions The creation of our Global Sustainability Advisory Services to maximize impact for our clientsAmsterdam, September 30, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announces its commitment to accelerate the transition to a net zero world, in which greenhouse gas emissions no longer contribute to climate change. A newly formed Global Sustainability Advisory Services team will allow...

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plcBarhemsys® and Byfavo® launches continue to show strong progress gaining formulary access in 107 additional accounts over the past 3 months For Barhemsys – 260 accounts on formulary with >80% win rate to date and well on track to meet annual formulary goal (300 accounts) by year end For Byfavo – 95 accounts on formulary with >90% win rate to date, and on track to meet our annual formulary goal (150 accounts) by year endCambridge, UK and Indianapolis, US – 30 September 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care...

Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149 against aflibercept THR-149 is a potent plasma kallikrein inhibitor for the treatment of the 40-50% of DME patients who respond suboptimally to anti-VEGF therapy Leuven, BE, Boston, MA, US – September 30, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, today announced positive data from Part A of its Phase 2 study (“KALAHARI”) of THR-149, a plasma kallikrein inhibitor, for the treatment of DME. Based on these data the Company has decided to move the highest dose of THR-149 (0.13mg) into Part B of the study, which is expected to begin...